Chief Scientific Officer
Synairgen Research Limited
Southampton, England, United Kingdom
Synairgen is a specialist respiratory biotech company whose primary focus is developing our investigative inhaled IFN-β (SNG001) for the treatment of severe viral lung infections, including COVID-19, as potentially the first host-directed, broad-spectrum antiviral treatment delivered directly into the lungs. Dr Phillip Monk joined Synairgen in October 2006 as Head of Bioscience Development and was appointed to the Board as Chief Scientific Officer in September 2009. Phillip was previously Director of the Respiratory and Inflammation Biology group at Cambridge Antibody Technology (‘CAT’) and was discovery/early development project manager for tralokinumab, an anti-IL-13 therapeutic antibody, now an approved treatment for moderate-to-severe atopic dermatitis. Prior to joining CAT, he worked at Bayer AG within the respiratory disease therapeutic area, focusing on the development of novel therapies for asthma, COPD and cystic fibrosis.
I do not have any relevant financial / non-financial relationships with any proprietary interests.
Friday, October 21, 2022
2:35 PM – 2:45 PM US ET